Multifunctional heart attaching and supporting device and pericardial fluid collecting system and method

By collecting pericardial fluid and administering drugs in situ using a multifunctional cardiac attachment support device, the problems of frequent open-chest surgery and limited drug therapy in the treatment of heart failure have been solved. This enables precise collection and biochemical testing of pericardial fluid, forming a closed-loop treatment mechanism and improving the accuracy of cardiac function and drug development.

CN118902499AActive Publication Date: 2024-11-08CHINA PHARM UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410936361.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-08
Estimated Expiration
2044-07-12

AI Technical Summary

Technical Problem

Existing technologies for the treatment of heart failure suffer from problems such as frequent open-chest surgeries, high risks of thrombosis and infection, lack of biofeedback mechanisms in drug therapy, and inaccurate pericardial fluid collection, leading to limited treatment options and difficulties in drug development.

Method used

A multifunctional cardiac attachment support device is designed, which uses a biomimetic suction cup structure to collect pericardial fluid and connects it to an extension tube through a hollow tube to achieve in situ cardiac drug delivery and biochemical detection. Combined with a peristaltic pump system for pericardial fluid collection, it avoids blood contamination and provides accurate biochemical indicator monitoring and treatment.

Benefits of technology

It enables multi-faceted treatment for heart failure patients, provides precise monitoring and treatment of biochemical indicators, reduces the risk of thrombosis and infection, forms a closed-loop monitoring-treatment-feedback mechanism, and improves the accuracy of drug therapy and cardiac function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902499A_ABST
    Figure CN118902499A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medical instruments, and discloses a multifunctional heart attaching and supporting device and a pericardial fluid collecting system and method. According to the multifunctional heart attaching and supporting device, pericardial fluid is mainly collected through a bionic suction cup structure on the inner side of the device, meanwhile, heart in-situ drug delivery can be achieved, according to the pericardial fluid collecting system and method, pericardial fluid is collected through the device, then biochemical detection is conducted, and the pericardial fluid can be accurately collected. According to the invention, early physical adjuvant therapy and late administration can be taken into consideration, administration is more localized and precise, disease development can be monitored through pericardial fluid, the therapeutic effect can be fed back, a'monitoring-treatment-feedback 'closed loop is formed, early intervention and early treatment are realized, and the treatment effect is improved. The treatment of heart failure is not limited to pure drug treatment and physical constraint treatment any more.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to a multifunctional heart attachment support device, a pericardial fluid collection system and a collection method. Background Art

[0002] Heart failure, also known as HF, refers to a syndrome in which the cardiac output is reduced due to primary heart damage and cannot meet the metabolic needs of tissues under normal venous return. After heart failure occurs, the heart's pumping function is insufficient, the cardiac output is reduced, and the ventricles are remodeled and thickened in the late stage, so the cardiac output cannot meet the normal activities of the body. It manifests as decreased exercise tolerance. Even if the normal activities are slightly farther or last longer, they will cause chest tightness, shortness of breath, fatigue and other symptoms of insufficient blood supply, which seriously affects the quality of life of patients.

[0003] For early stage of heart failure, the commonly used treatment method is oral systemic administration. At present, new drug delivery methods are being studied in the laboratory stage, such as one-time cardiac hydrogel patches, which can store therapeutic drugs or cells and release drugs or cells locally in the heart after implantation, thereby achieving the therapeutic effect. For example, the cardiac microneedle patch uses cardiac stromal cells as the matrix. Transplanting it to the damaged heart wall can promote myocardial regeneration (Tang, J., Wang, J., Huang, K., Ye, Y., Su, T., Qiao, L., Hensley, MT, Caranasos, TG, Zhang, J., Gu, Z., & Cheng, K. (2018). Cardiac cell-integrated microneedle patch for treating myocardial infarction. Science advances, 4(11), eaat9365. https: / / doi.org / 10.1126 / sciadv.aat9365). The disadvantage is that each drug delivery requires open-chest surgery. However, each time a cardiac patch is implanted to deliver medication, it requires open-chest surgery, which causes great damage and is limited to single emergency treatments.

[0004] For end-stage heart failure, commonly used treatments include heart transplantation, or the use of ventricular assist devices combined with drug-assisted therapy. The most common implantable long-term left ventricular assist device on the market and currently the most commonly used in clinical practice is the blood pump ventricular assist device (LVAD), such as the domestic Chongqing Yongrenxin and the imported HeartMate. The blood pump consists of a pump body, pipes and a power system, connecting the left ventricle and the aorta. It actively transfers blood from the left ventricle to the aorta to reduce the burden on the heart and improve the body's perfusion, thereby "treating" end-stage heart failure. However, due to its treatment mechanism of transporting blood in direct contact with blood, patients need to take anticoagulants for a long time, but there is still a chance of complications such as thrombosis and infection if they live with the machine for a long time, which undoubtedly increases the economic burden on patients and reduces their quality of life. The ventricular assist devices developed in the laboratory stage include non-blood-contact devices that rely on pneumatic or hydraulic forces, such as the Soft Robotic Sleeve, which mainly includes: a pneumatic transmission device, an air pump, and a soft sleeve. The above device mainly uses compressed air to drive the soft sleeve to compress and rotate, thereby imitating the heart movement of a normal person (Roche, ET, Horvath, MA, Wamala, I., Alazmani, A., Song, SE, Whyte, W., Machaidze, Z., Payne, CJ, Weaver, JC, Fishbein, G., Kuebler, J., Vasilyev, NV, Mooney, DJ, Pigula, FA, & Walsh, CJ (2017). Soft robotic sleeve supports heart function. Science translational medicine,9(373),eaaf3925.https: / / doi.org / 10.1126 / scitranslmed.aaf3925). Although it wraps around the periphery of the heart and does not come into direct contact with the blood, it is still functionally the same as other ventricular assist devices. It is difficult to organically combine it with other heart failure treatment methods. It can only perform physical support therapy. It has obvious singleness and limitations in use, especially it cannot perform direct biological monitoring and drug intervention. For example, after heart failure occurs, the changes in pericardial fluid are closely related to the state of the heart. During the pathological process of the heart, the levels of various active biochemical factors in the pericardial fluid change significantly, including hormones, neurotransmitters, cytokines, and local growth and apoptosis factors.However, the current method of obtaining pericardial fluid is generally to collect it by puncture. The pericardial fluid obtained by this collection method cannot avoid the mixing of other body fluids in the thoracic cavity, and it is difficult to form a relatively accurate feedback mechanism between drugs and changes in pericardial fluid components. In the field of drug treatment and research and development for heart failure, it is also necessary to collect pericardial fluid for component analysis in order to establish the correlation between relevant components in the pericardial fluid and medication. The lack of the above-mentioned accurate feedback mechanism has also restricted the progress of heart failure drug research and development.

[0005] The inventor's research group of the present application has previously disclosed a patent document CN107049232B, which provides an attached cardiac function monitoring and / or intervention system, including a cardiac support device and a cardiac function monitoring device and / or intervention device, wherein the cardiac support device is coated on the outer surface of the ventricle and / or atrium or supported and attached to the inner surface of the heart cavity, and the cardiac function monitoring device is connected to a physiological and biochemical sensor, which detects or senses changes in the physiological and biochemical parameters of the inner or outer surface of the heart, and transmits them to the cardiac function monitoring device through wireless technology or wired wires; the intervention device is selected from one or more of a pressure intervention device, an electric / magnetic stimulation intervention device, or a drug intervention device. Although the attached cardiac function monitoring and / or intervention system disclosed by it can realize direct local endocardial / epicardial precise physiological and biochemical function indicator monitoring and direct local endocardial / epicardial precise positioning drug administration or electric / magnetic stimulation or ventricular pressure regulation, it organically combines monitoring with treatment to improve the patient's heart failure state. However, the biochemical parameters obtained by it are indirectly obtained through sensors, and the range and accuracy of indicators that can be detected have certain limitations. Summary of the invention

[0006] In order to overcome the shortcomings of the above-mentioned prior art, the present invention provides a multifunctional heart attachment support device, which provides a basis for multi-modal treatment of patients with heart failure. The device mainly collects pericardial fluid through the bionic suction cup structure on its inner side and can also realize in situ drug delivery to the heart. The present invention also provides a pericardial fluid collection system and collection method, that is, pericardial fluid is collected by the device provided by the present invention, and then biochemically tested. The biochemical indicators that can be detected include but are not limited to common indicator proteins of cardiovascular diseases such as brain natriuretic peptide and cardiac troponin.

[0007] The technical solution adopted by the present invention is:

[0008] In the first aspect, the present invention provides a multifunctional cardiac patch support device, which is made of elastic photosensitive resin liquid material or soft photosensitive hydrogel material through mold manufacturing or 3D additive manufacturing, and then cured by ultraviolet light. It should be noted that the mold manufacturing includes traditional mold manufacturing methods such as "multi-level shunt bridge" or "step-type" extrusion; Figure 1As shown, the multifunctional heart attachment support device includes a mesh structure, an extension column tube and an extension tube. The mesh structure is composed of criss-crossed hollow tubes, and the mesh structure is customized in size according to the heart shape of the implanted object, so that the mesh structure can be wrapped and closely attached to the epicardium on the surface of the heart after being implanted in the chest cavity, providing physical support for the enlarged heart and limiting the adverse expansion of the ventricle; a plurality of microporous suction cups are arranged on the wall of the hollow tube on the inner side of the mesh structure, and the center of the microporous suction cup has a micropore, and the micropore is connected to the hollow tube to which it is attached, and the hollow tube is connected to one end of the extension column tube, and the other end of the extension column tube is used to nest the extension tube, and the terminal end of the other end of the extension tube can be buried subcutaneously and can be connected to an extracorporeal tube to collect pericardial fluid for disease course analysis, providing a basis and foundation for precise intervention; the extension tube can also be connected to a drug pump, and the micropores can be used to achieve fixed-point, timed and quantitative precise drug delivery, so as to achieve real-time interactive intervention of internal and external devices in heart failure.

[0009] Among them, the viscosity range of the elastic photosensitive resin liquid material is 960~1000mpa.s, and the physical properties of the elastic photosensitive resin liquid material after being cured by ultraviolet light with a wavelength of 390~420nm need to meet the following requirements: hardness 70~80D; elastic modulus 1.8~2.4Mpa; tear strength 40~48.2KN / M, tensile strength 7~7.9Mpa, elongation at break 200~255.1%; preferably, the elastic photosensitive resin liquid material is a white x27 elastic photosensitive resin produced by Polyxin Materials Co., Ltd. and the ultraviolet light curing wavelength is 400nm.

[0010] The soft photosensitive hydrogel material is a mixture of acrylamide and ureide compounds in an organic solution with a viscosity of 500 to 800 mPa.s, wherein acrylamide and ureide compounds account for 2% to 25% of the total mass of the mixture respectively, and the implant device can be printed by a 3D printer at a wavelength of 390 to 420 nm.

[0011] The soft photosensitive hydrogel material is preferably a mixture of N-acrylamide semicarbazide and acrylamide in an organic solution, wherein the percentage of N-acrylamide semicarbazide and acrylamide in the total mass of the mixture is 10% to 25%, and the mass ratio of N-acrylamide semicarbazide to acrylamide is 1:(1 to 1.5).

[0012] After the device is implanted in the chest cavity of the patient, the inner wall suction cup structure forms a tiny negative pressure to collect epicardial exudate, i.e. pericardial fluid. The hollow tubes of the extension column tube and the mesh structure are both hollow structures and interconnected. The epicardial exudate flows through the central micropores of the suction cup through the hollow tube, and then converges through the hollow tube and flows through the extension column tube and the extension tube in turn. Finally, it can be led out of the body by negative pressure for analysis of the disease progression. Subsequently, the device can be used to implement targeted cardiac in situ drug delivery intervention according to the analysis results. After the device is implanted in the body, the end of the extension tube is buried subcutaneously, and the external drug pump can be connected at any time. The therapeutic drug reaches the epicardium directly, and the epicardium can be delivered in situ at a fixed time, quantitatively, and accurately. In addition to being able to realize the above-mentioned pericardial fluid collection and precise treatment functions, the device can also provide mechanical support for the damaged heart, reduce the ventricular wall stress of the damaged heart, and limit the adverse remodeling of the heart. Moreover, the hollow design will not cause the problem of cardiac effusion retention.

[0013] Therefore, this device can be used for drug administration in patients with early heart failure, and compared with other drug administration methods, the drug administration is more accurate; it can also be used for patients with late-stage heart failure to achieve physical support, and can also collect epicardial effusion, i.e. pericardial fluid, in an almost non-invasive way to analyze the progression of the disease, and then perform precise in situ cardiac drug administration. When necessary, epicardial effusion feedback can be collected to form a closed-loop management.

[0014] In a second aspect, the present invention provides a pericardial fluid collection system, the system comprising the multifunctional heart attachment support device of the first aspect, and also comprising a negative pressure container, an A pipe, a B pipe and a peristaltic pump, wherein the subcutaneous lead-out end of the extension tube of the device is connected to one end of the A pipe, the other end of the A pipe is inserted into the lower space of the negative pressure container, one end of the B pipe is inserted into the upper space of the negative pressure container, and the other end of the B pipe is connected to the peristaltic pump;

[0015] In the third aspect, the present invention also provides a method for collecting pericardial fluid, that is, using the collection system provided in the second aspect above, adjusting the speed of the peristaltic pump to maintain a micro-negative pressure environment, when the air pressure in the negative pressure container is stable, the epicardial exudate slowly and evenly flows out along the A pipe, and the epicardial exudate can be collected. During the collection process, the negative pressure container needs to be placed in ice water at 0°C to avoid protein degradation in the sample.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] The multifunctional cardiac attachment support device provided in the first aspect of the present invention has an overall pipeline structure design, which is the basis for the device to achieve multifunctionality. The chest cavity space is used to accommodate the implant device, cleverly avoiding its contact with blood, effectively reducing the risk of complications such as thrombosis and infection; the horizontal and vertical crisscrossing hollow tubes can be buried subcutaneously through extension tubes led out from extension column tubes, and can be connected to external instruments through the tubes at the subcutaneous ends when needed. The bionic microporous suction cup structure design of the inner wall provides pericardial fluid collection and in situ cardiac drug delivery functions. The collected pericardial fluid can be used for disease analysis, and in situ cardiac drug delivery can also be performed according to clinical needs, thereby realizing pericardial fluid sampling, analysis and in situ intelligent and precise cardiac drug delivery.

[0018] The pericardial fluid collection system provided by the second aspect of the present invention and the pericardial fluid collection method provided by the third aspect mainly utilize the micro-negative pressure generated by the microporous suction cup structure of the inner wall of the multifunctional heart attachment support device to collect pericardial fluid. Compared with the traditional pericardial fluid collection method, it can avoid the mixing of other body fluids in the thoracic cavity and collect pericardial fluid more accurately. The in vivo experiment of rats shows that according to the collection results of Example 1 in the specific embodiment of the present invention, compared with the device without the suction cup structure, the rat pericardial fluid collected by the present invention is clearer, the collected volume is smaller, and no other body fluids (such as blood) are mixed. According to Example 2 in the specific embodiment of the present invention, the pericardial fluid collected from rats with myocardial infarction was subjected to proteomic analysis, and many valuable potential therapeutic targets were found. DNM1L was finally selected as the drug intervention target, and the cardiac function of rats with myocardial infarction was significantly improved after the in situ drug administration intervention of the heart. It shows that the closed-loop intervention treatment method based on the present invention of "collecting pericardial fluid-analyzing targets / conditions-in situ drug administration of the heart-pericardial fluid analysis feedback efficacy" is very effective.

[0019] The multifunctional cardiac patch support device provided by the present invention can take into account both early physical-assisted therapy and late drug administration, and the drug administration is more localized and precise. At the same time, the progression of the disease can be monitored and the treatment effect can be fed back through pericardial fluid, forming a "monitoring-treatment-feedback" closed loop, achieving early intervention and early treatment, so that the treatment of heart failure is no longer limited to simple drug therapy and physical restraint therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 A schematic diagram of the multifunctional cardiac attachment support device of the present invention and its implantation position;

[0021] Figure 2 Some photos of the process of making the multifunctional heart attachment support device in Example 1;

[0022] Figure 3 Partial operation photos of the establishment of the myocardial infarction model, implantation of the device and collection of pericardial fluid in Example 1; Figure 4The figures are photos of the assembly of the implant device, the negative pressure container, the A pipe, the B pipe and the peristaltic pump in Example 1, wherein Figure a is a partial photo of the insertion positions of the A pipe and the B pipe in the negative pressure container; Figure b is a schematic photo of the assembly of the pericardial fluid collection system;

[0023] Figure 5 This is a schematic diagram of the operation of collecting epicardial effusion using the pericardial fluid collection system in Example 1;

[0024] Figure 6 The following are comparison photos of epicardial effusion samples collected by the pericardial fluid collection system of the present invention and those collected by conventional devices in Example 1; wherein, Figure a is the epicardial effusion collected by the pericardial fluid collection system of the present invention, and Figure b is the epicardial effusion sample collected by the conventional device;

[0025] Figure 7 This is a schematic diagram of the location of the micropore structure of a conventional device without a suction cup structure used for comparison in Example 1;

[0026] Figure 8 The volume comparison of the samples collected by the collection system of the present invention and the samples collected by the conventional device in the AMI group in Example 1; the volume comparison of the samples collected by the collection system of the present invention in different groups;

[0027] Fig. 9 Schematic diagram of the structure and dimensions of the implant device designed for the heart of experimental rats in Example 1. DETAILED DESCRIPTION

[0028] The present invention is further described below in conjunction with embodiments and drawings.

[0029] Example 1: Experiment on collecting pericardial fluid from rats with acute myocardial infarction using the pericardial fluid collection system of the present invention

[0030] 1.1 Experimental Materials

[0031] Experimental animals: Thirty male Sprague-Dawley (SD) rats (250 ± 20 g) were used in this experiment. All animals were purchased from Hangzhou Medical College with a quality license number of SCXK (Zhejiang) 2019-0002 and a certificate number of 20210712Aazz0100000252. All animal experiments followed the Animal Experiment Guidelines and Animal Experiment Ethics Guidelines of China Pharmaceutical University and were in accordance with the Declaration of Helsinki.

[0032] Experimental reagents: Flexible resin was purchased from Polyxin Materials; ultrapure water was purchased from Fisher Chemical; sodium chloride was purchased from Nanjing Chemical Reagent Co., Ltd.; chloral hydrate was purchased from Sinopharm Chemical Reagent Co., Ltd.; anhydrous ethanol was purchased from Nanjing Chemical Reagent Co., Ltd.; disodium hydrogen phosphate dodecahydrate was purchased from Nanjing Chemical Reagent Co., Ltd.; sodium hydroxide was purchased from Xilong Science Co., Ltd.; sodium bicarbonate was purchased from Nanjing Chemical Reagent Co., Ltd.; potassium dihydrogen phosphate was purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd.; potassium chloride was purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd.; iodine disinfectant was purchased from Shandong Anjie High-tech Disinfection Technology Co., Ltd.; dipotassium hydrogen phosphate was purchased from Nanjing Chemical Reagent Co., Ltd.

[0033] Experimental instruments: Animal physiological function experimental system BL-420S was purchased from Chengdu Taimeng Co., Ltd.; small animal ventilator HX-300S was purchased from Chengdu Taimeng Co., Ltd.; 1 / 10,000 electronic balance AL204 was purchased from Mettler-Toledo Instrument Co., Ltd.; pressure converter YP100 was purchased from Beijing Xinhang Xingye Science and Technology Trade Co., Ltd.; pure water working instrument SMART-N was purchased from Shanghai Kanglei Analytical Instrument Co., Ltd.

[0034] 1.2 Experimental methods

[0035] Device structure and size design: Fig. 9 As shown, the specific parameters of the product structure of the device of this embodiment are as follows: the device obtains various specific parameters by measuring the major axis and minor axis of the rat heart. The main body diameter of the two extension column tubes at the top of the device is 2mm and the length is 10mm. The inner diameter of the largest circle of the main body of the device is 13mm and the outer diameter is 15mm; the inner diameter of the smallest circle is 3mm and the outer diameter is 5mm. In addition, the inner diameter of the hollow pipe is 0.6mm, the wall thickness is 0.4mm, and microporous suction cups are evenly distributed on the inner wall. The overall diameter of the microporous suction cup is 1.2mm, and the micropore diameter of the microporous suction cup is 300μm.

[0036] Fabrication of implantable devices: Figure 2 As shown, first, Figure 2 As shown in Figure a, the electronic 3D drawings of the device are sliced ​​and converted into a 3D printing format using 3D printing software; Figure 2As shown in Figure b, select the poly-new material application elastic resin X23 as the elastic liquid photosensitive resin with a viscosity of 980mpa.s. Take 100-200ml of resin and add it to the material tray of the 3D printer. Printer parameter settings: light curing wavelength 395-405nm, accuracy, i.e. layer thickness 0.05mm, number of layers 15-25, bottom layer exposure time 20-25s, regular exposure time 1.7-3.5s, attachment molding time 30.0s, shell wall thickness 2.0mm, filling wall thickness 1.0mm; each layer curing time 0.2s, use model: Proxima 6.0 3D printer for printing, the total printing time is about 1h30min, remove the model after printing, put it in anhydrous ethanol ultrasonic cleaning for 10min, cut off the support column, and place it at a wavelength of about 400nm for secondary curing for 5min to obtain the finished product of the microporous suction cup-like device as shown in the figure Figure 2 As shown in Figures d, e and f, the weight of the finished products of the same batch is 0.7-0.8g. The finished product samples were tested for mechanical properties, with a hardness of 75D, an elastic modulus of 2.1Mpa, a tear strength of 48.2KN / M, a tensile strength of 7.9Mpa, and an elongation at break of 255.1%. In order to reflect the collection effect of the microporous suction cup of the multifunctional heart attachment support device provided by the present application, a conventional mesh device with only micropores and no bionic suction cup was made according to the device size, material and manufacturing process of the present application. Figure 7 As shown, the structural difference between the conventional mesh device used for comparison and the multifunctional heart attachment support device provided by the present invention is that the conventional device is directly provided with a plurality of micropores on the hollow tube wall inside the mesh structure, without a suction cup structure.

[0037] Animal grouping: Thirty male Sprague-Dawley (SD) rats (250±20g) were used in this experiment. All animals were purchased from Hangzhou Medical College with a quality license number of SCXK (Zhejiang) 2019-0002 and a certificate number of 20210712Aazz0100000252. All animal experiments followed the Animal Experiment Guidelines and Ethical Guidelines of Animal Experiments of China Pharmaceutical University and the Declaration of Helsinki. They were divided into an acute myocardial infarction group (AMI) and a sham operation group (Control). The acute myocardial infarction group (AMI) was a myocardial infarction model established by ligating the left anterior descending branch of the animal coronary artery; the sham operation group (Control) was a thoracotomy in which a needle and thread were passed through the ligation point but not ligated.

[0038] The specific process of establishing the acute myocardial infarction (AMI) model is as follows: all rats were weighed; Figure 3 In Figure a, rats were anesthetized by intraperitoneal injection of 10% chloral hydrate at a dose of 0.3 g / kg; after anesthesia, the rats were thoracotomized by invasive surgery, such as Figure 3As shown in Figures b, c, and d, fix the rat in a supine position and use ophthalmic scissors to cut the skin 1.5 to 2.0 cm above the xiphoid process and 2 to 3 mm to the right. Figure 3 In Figures e and f, after blunt separation of the skin with hemostats, the pectoralis major muscle can be seen overlying the serratus anterior muscle. The pectoralis major muscle is first clamped and bluntly separated from the serratus anterior muscle, and then the pectoralis major muscle is lifted up. The serratus anterior muscle is seen overlying the ribs. The serratus anterior muscle is clamped and bluntly separated from the ribs. The separated muscles and skin are stretched open with an eyelid spreader to expose the intercostal space between the third and fourth ribs, forming a cardiac surgical field of view. Figure 3 Figure g in the figure, at this time, forceps are used to gently tear the pericardium on the surface of the heart, find the position of the left coronary vein of the heart, and use 6.0 sutures to ligate the left anterior descending coronary artery (LAD) 1 to 2 mm below the tip of the left auricle. The occurrence of acute myocardial infarction is confirmed by the color change of the ischemic area of ​​the heart and the characteristic changes of the electrocardiogram. The acute myocardial infarction model rat surgery group, i.e., the AMI group, is divided into two groups, one group is used to implant the multifunctional heart attachment support device designed and manufactured by the present application, and the other group is used to implant the above conventional device; another sham operation group is set up, the sham operation group does not ligate the left anterior descending coronary artery but only threading, and the rest of the operation is the same as before, and the same sham operation group is also divided into two groups, one group is used to implant the multifunctional heart attachment support device designed and manufactured by the present application, and the other group is used to implant the above conventional device.

[0039] Device implantation: According to the above grouping, the device designed and manufactured by the present application and the conventional device for comparison were implanted into the corresponding rats according to the grouping; it should be noted that because the experimental subjects are rats, which are relatively small, and in order to simplify the experimental materials and experimental operations, in this experimental example, the A channel also serves as an extension tube; the implantation adopts an invasive minimally invasive thoracotomy, and the sterilized device is folded and sent into the apex of the rat's heart. After reaching the apex, the device is unfolded, and the extension column tube of the device is clamped with tweezers, and the device is put on from the apex to the bottom of the heart. This process must be gentle to avoid damaging other organs; Figure 3 As shown in Figures h, i and j, the extension column tube of the device is passed through the second and third intercostal spaces of the rat, one end of the A tube is clamped with tweezers and inserted into the hollow extension column tube, and then the A tube is led from the subcutaneous part of the forelimb to the subcutaneous part of the neck and connected to the negative pressure container; Figure 3 As shown in Figures k and l, after everything is completed, the muscle layers are sutured layer by layer. At the same time, attention is paid to pumping back the air in the rat's chest cavity to form a negative pressure in the chest cavity to help the rat recover spontaneous breathing. After the operation, the rat is placed on a heating plate to maintain its body temperature to prevent postoperative hypothermia.

[0040] Pericardial fluid collection: Figure 4As shown, the subcutaneous extracorporeal conduits of the four groups of rats implanted with the device were connected to the A conduit of the negative pressure container, and the B conduit of the negative pressure container was connected to the peristaltic pump. The speed of the peristaltic pump was adjusted to maintain a slightly negative pressure environment. When the air pressure in the negative pressure container was stable and the epicardial exudate in the A conduit flowed out slowly and evenly, the epicardial exudate was collected. Figure 5 As shown, during this process, the negative pressure container was always immersed in ice water (0°C) to prevent protein degradation in the sample. After continuous collection for 6 hours, the sample was transferred to a centrifuge tube and centrifuged at 4°C, 2000×g for 10 minutes. After measuring the sample volume, the supernatant was taken and frozen at -80°C.

[0041] 1.3 Experimental results

[0042] The properties and volume of pericardial fluid collected from the rats in the above four groups were statistically analyzed. Figure 6 As shown in Figure a of FIG. 1 , the multifunctional cardiac attachment support device with microporous suction cups of the present invention can successfully collect epicardial exudate, and the fluid is a light yellow clear liquid observed by the naked eye, without visible impurities and blood. Figure 6 Figure b shows the epicardial exudate collected by a conventional device without a suction cup structure. It is turbid in appearance and reddish and yellow in color. Figure 8 As shown, the statistical analysis results of the epicardial exudate volume collected by the multifunctional cardiac attachment support device with microporous suction cups of the present invention show that the sample volume of the sham operation group, i.e., the control group, is 0.97±0.17mL, and the sample volume of the acute myocardial infarction group, i.e., the AMI group, is 1.25±0.16mL. Compared with the blank group, the epicardial exudate volume of the AMI group is significantly more than that of the sham operation group, with a very significant difference (P<0.01); the statistical analysis of the sample volume of the same group of conventional devices and microporous suction cup-like devices is performed. Compared with the conventional device, the sample volume collected by the microporous suction cup-like device in the blank group and the AMI group is significantly less than that of the conventional device (P<0.01), which is statistically significant. It shows that the multifunctional cardiac attachment support device with microporous suction cups of the present invention has a higher specificity for epicardial exudate, avoiding the blood at the incision, the thoracic exudate, and the exudate on the surface of other organs from being collected simultaneously with the epicardial exudate.

[0043] Proteomic analysis of pericardial fluid after myocardial infarction and screening of differentially expressed proteins (DEPs): A non-labeled proteomic analysis was performed on the epicardial exudate collected by the conventional device, and a total of 651 proteins were identified, of which 140 were upregulated and 98 were downregulated. A TMT-labeled proteomic analysis was performed on the epicardial exudate collected by the multifunctional heart attachment support device with microporous suction cup based on the present invention, and a total of 1292 proteins were identified, of which 77 were upregulated and 49 were downregulated. Protein interaction network (PPI) analysis revealed that ubiquitin-60S ribosomal protein L40 (Uba52), eukaryotic elongation factor 2 kinase (Eef2k), dynamin-related protein 1 (DNM1L), heat shock homologous protein 71kDa (Hspa8), 60S ribosomal protein L4 (Rpl4), eukaryotic translation initiation factor 3 subunit I (Eif3i), integrin αM (Itgam), 60S ribosomal protein L13a (Rpl13a), nucleoside diphosphate kinase B (Nme2), protein disulfide isomerase A3 (Pdia3), 14-3-3 protein gamma (Ywhag), protein phosphatase 2 (Ppp2r1a) and other proteins were at key nodes in the PPI network, which were mainly involved in myocardial contraction, protein synthesis regulation, complement and inflammatory response.

[0044] In summary, the microporous suction cup biomimetic device improves the specificity of pericardial fluid collection and makes proteomics results more accurate and reliable. Laboratory proteomics analysis of epicardial effusion in the early stage after acute myocardial infarction found that most of the differentially expressed proteins in the pericardium have complex roles in the early stage of AMI and the compensatory adaptation process after ischemia, which may be potential targets for regulating the epicardium to promote cardiac repair.

[0045] Example 2: Experiment on in situ drug administration based on proteomic targets of collected pericardial fluid to intervene in myocardial infarction in rats

[0046] In order to explore new drug therapeutic targets for myocardial infarction, the top 5% of hub proteins in the pericardial fluid proteomics results were screened, and DNM1L was finally determined to be a potential therapeutic target for myocardial infarction (MI). This example intends to use the DNM1L protein inhibitor, Mdivi1, and administer it in situ to the epicardium of rats with MI through this device to prove the scientific nature of the target analysis.

[0047] 2.1 Experimental Materials

[0048] Experimental animals: 18 male Sprague-Dawley (SD) rats (250 ± 20 g) were used in this experiment. All animals were purchased from Hangzhou Medical College with a quality license number of SCXK (Zhejiang) 2019-0002. All animal experiments followed the Animal Experiment Guidelines and Animal Experiment Ethics Guidelines of China Pharmaceutical University and were in accordance with the Declaration of Helsinki.

[0049] Experimental reagents: Sodium chloride was purchased from Nanjing Chemical Reagent Co., Ltd.; chloral hydrate was purchased from Sinopharm Chemical Reagent Co., Ltd.; anhydrous ethanol was purchased from Nanjing Chemical Reagent Co., Ltd.; disodium hydrogen phosphate dodecahydrate was purchased from Nanjing Chemical Reagent Co., Ltd.; sodium hydroxide was purchased from Xilong Science Co., Ltd.; sodium bicarbonate was purchased from Nanjing Chemical Reagent Co., Ltd.; potassium dihydrogen phosphate was purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd.; potassium chloride was purchased from Shanghai Lingfeng Chemical Reagent Co., Ltd.; neutral gum sealing medium was purchased from Shanghai Shenggong Bioengineering Co., Ltd.; xylene was purchased from Nanjing Chemical Reagent Co., Ltd.; glacial acetic acid was purchased from Nanjing Chemical Reagent Co., Ltd.; concentrated hydrochloric acid was purchased from Nanjing Chemical Reagent Co., Ltd.; eosin was purchased from Beijing Chemical Reagent Co., Ltd.; hematoxylin was purchased from Beijing Chemical Reagent Co., Ltd.; iodine disinfectant was purchased from Shandong Anjie High-tech Disinfection Technology Co., Ltd.; sodium heparin was purchased from Beijing Solebow Technology Co., Ltd.; TM-100 medical coupling agent was purchased from Tianjin Jinya Technology Development Co., Ltd.; and potassium dihydrogen phosphate was purchased from Nanjing Chemical Reagent Co., Ltd.

[0050] Experimental instruments: Animal physiological function experimental system BL-420S was purchased from Chengdu Taimeng Co., Ltd.; small animal ventilator HX-300S was purchased from Chengdu Taimeng Co., Ltd.; 1 / 10,000 electronic balance AL204 was purchased from Mettler-Toledo Instrument Co., Ltd.; pressure converter YP100 was purchased from Beijing Xinhang Xingye Science and Technology Trade Co., Ltd.; pure water working instrument SMART-N was purchased from Shanghai Kanglei Analytical Instrument Co., Ltd.; small animal ultrasound imaging system was purchased from Yum Medical Equipment Co., Ltd.; electric oven XMTD-8222 was purchased from Shanghai Jinghong Experimental Equipment Co., Ltd.

[0051] 2.2 Experimental methods

[0052] Animal grouping: Eighteen SD rats (200-220g, male) were randomly divided into three groups: sham operation group (Control group), acute myocardial infarction group (AMI), and myocardial infarction treatment group (Treatment); the Control group was a sham operation group, in which only threading was performed after thoracotomy without ligation; the AMI group was given a myocardial infarction model without any treatment; the Treatment group was implanted with a microporous suction cup device after modeling, and within 1 day after coronary artery ligation, mdivi-1 was injected in situ through an extension tube at a dose of 1.2 mg / Kg.

[0053] Disease model establishment: The acute myocardial infarction (AMI) model was established as described in Example 1.

[0054] Methods and indicators for evaluating cardiac function include echocardiography and hemodynamics. Echocardiography detects indicators such as left ventricular ejection fraction (LVEF%), left ventricular fractional shortening (LVFS%), left ventricular internal diameter (LVIDs) and left ventricular internal diameter (LVIDd), which are important indicators for evaluating myocardial infarction. Hemodynamics is to obtain values ​​such as left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), maximum rate of increase of left ventricular pressure (+dp / dtmax), and maximum rate of decrease of left ventricular pressure (-dp / dtmax).

[0055] Device implantation: The device implantation procedure was as described in Example 1.

[0056] 2.3 Experimental Results

[0057] The results of echocardiography are shown in Table 1. The data of each group in Table 1 are expressed as mean ± standard deviation (Mean ± SD). (*** represents P < 0.001 compared with the sham operation group; #, ## represent P < 0.05 and P < 0.01 compared with the acute myocardial infarction group, respectively.

[0058] Table 1: Left ventricular ejection fraction (LVEF%), left ventricular fractional shortening (LVFS%), left ventricular internal diameter at systole (LVIDs), and left ventricular internal diameter at diastole (LIVDd) in each group of rats on day 28

[0059]

[0060] The data in Table 1 above show that compared with the acute myocardial infarction group, after the administration of Mdivi1 via the device, the left ventricular ejection fraction (LVEF%) and left ventricular fractional shortening (LVFS%) values ​​of the myocardial infarction rats were significantly increased.

[0061] The hemodynamic results are shown in Table 2 below. The data of each group are expressed as mean ± standard deviation (Mean ± SD); ** represents P < 0.01 compared with the Control group.

[0062] Table 2: Left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), maximum rate of increase and maximum rate of decrease (±dp / dtmax) of left ventricular pressure in each group of rats on day 28

[0063]

[0064] As can be seen from the above table, the maximum rate of increase of left ventricular intracardiac pressure (+dp / dtmax) value was higher in the myocardial infarction treatment group (Treatment group) compared with the acute myocardial infarction group (AMI group).

[0065] In summary, the experiment of Example 2 evaluates the cardiac function of rats in each experimental group through ultrasonic cardiography and hemodynamic data. The experimental results show that the administration of corresponding intervention drugs based on the pericardial fluid analysis target through the device can effectively increase the left ventricular systolic pressure (LVSP), left ventricular short-axis shortening fraction (LVFS%), and maximum rate of increase of left ventricular intraventricular pressure (+dp / dtmax) of rats after myocardial infarction, and improve the cardiac function of rats with myocardial infarction. Example 2 demonstrates the ingenuity and feasibility of the design of the present invention, and at the same time verifies the closed-loop treatment concept of "collecting body fluids-analyzing targets / conditions-precise intervention" based on the present invention, and preliminarily reflects the application prospects of the present device.

Claims

1. A multifunctional heart attachment support device, characterized in that: The multifunctional heart attachment support device is made of elastic photosensitive resin liquid material or soft photosensitive hydrogel material through mold manufacturing or 3D additive manufacturing, and then cured by ultraviolet light. The multifunctional heart attachment support device includes a mesh structure, an extension column tube and an extension tube. The mesh structure is composed of criss-crossed hollow pipes, and the mesh structure is customized in size according to the heart shape of the implanted object, so that the mesh structure can be wrapped and closely attached to the epicardium on the surface of the heart after being implanted in the chest cavity, providing physical support for the enlarged heart and limiting the adverse expansion of the ventricle; a plurality of microporous suction cups are arranged on the hollow pipe wall on the inner side of the mesh structure, and the center of the microporous suction cup has a micropore, and the micropore is connected to the hollow pipe to which it is attached, and the hollow pipe is connected to one end of the extension column tube, and the other end of the extension column tube is used to nest the extension tube, and the end of the other end of the extension tube can be buried subcutaneously and can be connected to an extracorporeal pipe.

2. A multifunctional heart attachment support device according to claim 1, characterized in that: The viscosity range of the elastic photosensitive resin liquid material is 960 to 1000 mpa.s. The physical properties of the elastic photosensitive resin liquid material after being cured by ultraviolet light with a wavelength of 390 to 420 nm must meet the following requirements: hardness 70 to 80D; elastic modulus 1.8 to 2.4 MPa; tear strength 40 to 48.2 KN / M, tensile strength 7 to 7.9 MPa, and elongation at break 200 to 255.1%.

3. A multifunctional heart attachment support device according to claim 2, characterized in that: The physical properties of the elastic photosensitive resin liquid material after being cured by ultraviolet light with a wavelength of 400nm meet the requirements of hardness 75D, elastic modulus 2.1Mpa, tear strength 48.2KN / M, tensile strength 7.9Mpa, elongation at break 255.1%, and the ultraviolet light curing wavelength is 400nm.

4. The multifunctional heart attachment support device according to claim 1, characterized in that: The soft photosensitive hydrogel material is a mixture of acrylamide and ureide compounds in an organic solution with a viscosity of 500 to 800 mPa.s, wherein acrylamide and ureide compounds account for 2% to 25% of the total mass of the mixture respectively, and can be printed by a 3D printer at a wavelength of 390 to 420 nm to produce the multifunctional heart attachment support device.

5. The multifunctional heart attachment support device according to claim 4, characterized in that: The soft photosensitive hydrogel material is a mixture of N-acrylamide semicarbazide and acrylamide in an organic solution, wherein the percentage of N-acrylamide semicarbazide and acrylamide in the total mass of the mixture is 10% to 25%, and the mass ratio of N-acrylamide semicarbazide to acrylamide is 1:(1 to 1.5).

6. A pericardial fluid collection system, characterized in that: The system includes a multifunctional heart attachment support device as described in claim 1, and also includes a negative pressure container, pipe A, pipe B and a peristaltic pump, the subcutaneous lead-out end of the extension column tube of the multifunctional heart attachment support device is connected to one end of pipe A, the other end of pipe A is inserted into the lower space of the negative pressure container, one end of pipe B is inserted into the upper space of the negative pressure container, and the other end of pipe B is connected to the peristaltic pump.

7. A method for collecting pericardial fluid, characterized in that: By using the collection system described in claim 6, the speed of the peristaltic pump is adjusted to maintain a slightly negative pressure environment. When the air pressure in the negative pressure container is stabilized, the epicardial exudate flows out slowly and evenly along the A pipe, and the epicardial exudate can be collected. During the collection process, the negative pressure container needs to be placed in ice water at 0°C to avoid protein degradation in the sample.

Citation Information

Patent Citations

  • Attaching-type heart function monitoring and / or intervening system

    CN107049232A

  • Rigid-flexible coupled heart fixator

    CN115869024A

  • Device to permit offpump beating heart coronary bypass surgery

    US20010041827A1

  • Apparatus and method for endoscopic cardiac mapping and lead placement

    US20040153098A1

  • High throughput drug screening of cancer stem cells

    US20210285933A1